Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Chris A. Rhoades"'
Autor:
Charles L. Shapiro, Bhuvaneswari Ramaswamy, Kari Kendra, Miguel A. Villalona-Calero, Marsha Hauger, Tim Moore, Ewa Mrozek, Padma Nadella, Chris A. Rhoades, Nancy J. Merriman, Holly Watson, Donn C. Young, Joan Allen
Publikováno v:
Clinical Breast Cancer. 7:141-145
Purpose This phase II study evaluated the safety and efficacy of weekly docetaxel and capecitabine in patients with metastatic breast cancer. Patients and Methods Thirty-nine patients with metastatic breast cancer received 30 mg/m 2 of docetaxel on d
Autor:
Anthony D. Elias, Bhuvaneswari Ramaswamy, Angela Dodley, Mark Morrow, Charles L. Shapiro, Nicole T. Kelbick, Chris A. Rhoades, Kari Kendra, S. Gail Eckhardt, Marsha Hauger, Helen X. Chen, Joan Allen
Publikováno v:
Clinical Cancer Research. 12:3124-3129
Purpose: To evaluate the safety and efficacy of bevacizumab and weekly docetaxel as first- or second-line therapy in patients with metastatic breast cancer (MBC).Patients and Methods: Twenty-seven MBC patients received i.v. bevacizumab at 10 mg/kg on
Autor:
Larry J. Schaaf, Gregory A. Otterson, John G. Kuhn, Ross E. Waite, J. Paul Monk, Chris A. Rhoades, Gary Phillips, Miguel A. Villalona-Calero, Manisha H. Shah, Denis C. Guttridge, Michael A. Caligiuri, Tamara Criswell
Publikováno v:
Journal of Clinical Oncology. 24:1852-1859
PurposeMaintaining dose-intensity with chemotherapeutic agents is hindered by a number of adverse effects including asthenia/fatigue. Tumor necrosis factor (TNF) is one of the cytokines responsible for the fatigue and cachexia associated with maligna
Publikováno v:
Hematology. 8:285-294
Intravenous immunoglobulin (IVIg) is a safe and effective therapy for the treatment of primary and secondary humoral immune deficiencies and autoimmune disorders. Both minor and more serious side effects may occur following IVIg administration in app
Autor:
Amit Agrawal, Roy E. Smith, Constance J. Bauer, Subir Nag, Donn C. Young, John C. Grecula, Jessie L.-S. Au, Reinhard A. Gahbauer, David E. Schuller, Chris A. Rhoades
Publikováno v:
Cancer Investigation. 19:127-136
From February 1993 through July 1994, 37 patients with stage III-IV squamous cell carcinomas of the oral cavity, oropharynx, or hypopharynx (stage II-IV) were registered to a treatment regimen consisting of preoperative continuous infusion cisplatin
Autor:
Roy E. Smith, James Allen, Federico P. Goldman, Pramod Sharma, David E. Schuller, Amit Agrawal, Donn C. Young, Hong Zhang, John C. Grecula, Chris A. Rhoades
Publikováno v:
Cancer. 89:2587-2596
BACKGROUND Previous Phase II trials evaluating paclitaxel as a single agent have produced objective response rates of 38–40%. However, in these studies patients had recurrent disease and had received previous treatment with chemotherapy, radiation,
Autor:
David S, Ettinger, Juan P, Arnoletti, Jon P, Gockerman, Charles, Handorf, Kathleen Anne, Havlin, Charlotte D, Jacobs, Milind, Javle, Larry, Kvols, Renato, Lenzi, Asif, Rashid, Chris A, Rhoades, John A, Ridge, Leonard, Saltz, Lawrence N, Shulman, Vernon K, Sondak, John A, Thompson, Przemyslaw, Twardowski, Weining, Zhen
Publikováno v:
Journal of the National Comprehensive Cancer Network : JNCCN. 3(2)
Autor:
Donn C. Young, David E. Schuller, John C. Grecula, Chris A. Rhoades, Amit Agrawal, Enver Ozer
Publikováno v:
Archives of otolaryngology--headneck surgery. 133(4)
Objective To determine the feasibility of, compliance with, and long-term survival with intensification treatment regimens for patients with advanced, resectable, previously untreated head and neck squamous cell carcinoma. Design Prospective phase 2
Autor:
Enver Ozer, John C. Grecula, Donn C. Young, David E. Schuller, Amit Agrawal, Chris A. Rhoades
Publikováno v:
The Laryngoscope. 116(4)
Background: Long-term disease control of an intensified treatment regimen for previously untreated stage III and IV resectable oral cavity, oropharyngeal, or hypopharyngeal squamous cell carcinoma was analyzed. Methods: Forty-three patients with prev
Autor:
Eric P. Lester, Merrill J. Egorin, Gary L. Rosner, Antonius A. Miller, John C. Byrd, Stephen A. Cullinan, Donna Hollis, Robert A. Parise, Frederick Millard, Mark J. Ratain, Chris A. Rhoades, D. Marc Rosen, Stuart M. Lichtman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 24(12)
Purpose To prospectively evaluate the pharmacokinetics and toxicity profile of paclitaxel in relation to patient age in adults ≥ 55 years old. Patients and Methods Paclitaxel was administered at 175 mg/m2 for 3 hours to 153 patients, 46 of whom wer